GSK Pakistan

GSK Pakistan, legally GlaxoSmithKline Pakistan Limited, is the Pakistani pharmaceutical company associated with the British healthcare group GSK plc. It is described in reference material as one of Pakistan's largest pharmaceutical companies and as the country's largest pharmaceutical company. The business focuses on prescription medicines and vaccines rather than the over-the-counter and consumer-health portfolio that was separated into a different Pakistani company. The company's Pakistani operating history began under the Glaxo Laboratories Pakistan name. It was listed on the Karachi Stock Exchange in 1951, giving the business a long presence in Pakistan's organized capital market and pharmaceutical sector. Its corporate identity later reflected the international consolidation of several major pharmaceutical businesses. In 2002, the combination of Glaxo Wellcome, SmithKline Beecham and GlaxoSmithKline's predecessor businesses created the global GSK structure, under which the Pakistani operation became known as GlaxoSmithKline Pakistan Limited. GSK Pakistan expanded its local portfolio through transactions involving other international pharmaceutical companies. In December 2008, it acquired Bristol-Myers Squibb's operations in Pakistan for approximately US$36.5 million, according to the cited reference material. In December 2010, it acquired Stiefel Laboratories' operations in Pakistan. These transactions broadened the company's local operating footprint and product responsibilities, although the available reference does not provide a detailed breakdown of the transferred brands or facilities. A major structural change occurred in the consumer-health business. In 2015, GlaxoSmithKline Consumer Healthcare Pakistan Limited was demerged from GlaxoSmithKline Pakistan Limited. The consumer-health company began operating independently in 2016 and was listed on the Pakistan Stock Exchange in 2017. In 2022, it changed its name to Haleon Pakistan. This separation established a clearer distinction between GSK Pakistan's prescription pharmaceutical and vaccine activities and Haleon Pakistan's consumer-health activities, including over-the-counter products. GSK Pakistan therefore represents the prescription-pharmaceutical and vaccine side of the former broader GSK presence in Pakistan. Its historical development combines a locally established Glaxo business, international pharmaceutical mergers, acquisitions of local operations from other multinational companies, and the later separation of consumer healthcare into Haleon. The available material confirms its continuing active presence in Pakistan but does not provide enough information to describe its current product brands, leadership team, manufacturing locations, revenue, or detailed market share without risking unsupported claims.

GSK Pakistan traces its Pakistani operations to Glaxo Laboratories Pakistan Ltd, which was listed on the Karachi Stock Exchange in 1951. The listing marked the company's established position in Pakistan's pharmaceutical economy and predates the creation of the modern GSK group by several decades. The present corporate identity emerged from the international consolidation of major pharmaceutical companies. Glaxo, Wellcome and SmithKline Beecham were previously separate businesses with substantial pharmaceutical operations. Their combination in 2002 created the GlaxoSmithKline group and brought the Pakistani operation under the GSK structure. In Pakistan, the resulting company operated as GlaxoSmithKline Pakistan Limited, commonly identified by the exchange symbol GLAXO. The company subsequently enlarged its local business through acquisitions. In December 2008, GSK Pakistan acquired the Pakistani operations of Bristol-Myers Squibb. The reported transaction value was approximately US$36.5 million. In December 2010, it acquired Stiefel Laboratories' operations in Pakistan. The available reference establishes the transactions but does not specify the precise brands, employees, facilities or therapeutic categories transferred in each deal. GSK's Pakistani business later underwent a significant portfolio and corporate separation. In 2015, GlaxoSmithKline Consumer Healthcare Pakistan Limited was demerged from GlaxoSmithKline Pakistan Limited. The consumer-health entity began operating independently in 2016 and was subsequently listed on the Pakistan Stock Exchange in 2017. In 2022, it adopted the name Haleon Pakistan. This transition separated consumer products and over-the-counter medicines from GSK Pakistan's core prescription-medicine and vaccine activities. The resulting structure leaves GSK Pakistan as the pharmaceutical company associated with GSK's prescription and vaccine business in Pakistan, while Haleon Pakistan represents the separately organized consumer-health operation. The sources available for this dossier do not provide reliable current information about GSK Pakistan's individual brands, factories, revenue, market share, senior executives or current corporate website. Those fields are therefore left blank rather than inferred from the wider GSK group.

• 2022

  Consumer-health successor renamed Haleon Pakistan

  [1]GSK Pakistanen.wikipedia.org

  The separately organized consumer-health company changed its name from GlaxoSmithKline Consumer Healthcare Pakistan Limited to Haleon Pakistan.

• 2015

  Consumer-health business demerged

  [1]GSK Pakistanen.wikipedia.org

  GlaxoSmithKline Consumer Healthcare Pakistan Limited was separated from GlaxoSmithKline Pakistan Limited.

• 2010

  Stiefel Laboratories Pakistan operations acquired

  [1]GSK Pakistanen.wikipedia.org

  GSK Pakistan acquired Stiefel Laboratories' operations in Pakistan.

• 2008

  Bristol-Myers Squibb Pakistan operations acquired

  [1]GSK Pakistanen.wikipedia.org

  GSK Pakistan acquired Bristol-Myers Squibb's operations in Pakistan for approximately US$36.5 million.

• 2002

  Formation of the GSK structure

  [1]GSK Pakistanen.wikipedia.org

  The combination of Glaxo, Wellcome and SmithKline Beecham businesses created the international GlaxoSmithKline group and shaped the identity of the Pakistani operation.

• 1951

  Listing of Glaxo Laboratories Pakistan

  [1]GSK Pakistanen.wikipedia.org

  Glaxo Laboratories Pakistan Ltd was listed on the Karachi Stock Exchange, establishing a documented public-market history in Pakistan.

A multinational-backed Pakistani pharmaceutical company focused on prescription medicines and vaccines, distinct from Haleon Pakistan's consumer-health portfolio.

• Pharmaceuticals

  Prescription medicines

  Prescription medicines are a core part of GSK Pakistan's business. The company manufactures and markets pharmaceutical products for use under medical supervision. The available reference does not identify the current individual brands or therapeutic areas in sufficient detail.

• Pharmaceuticals

  Vaccines

  Vaccines are identified as part of GSK Pakistan's principal business alongside prescription medicines. No product-level information is available in the supplied material to specify individual vaccine brands, indications or launch dates.

• 2015

  Demerger of consumer healthcareStrategy

  Background

  GSK separated its consumer-health activities from the prescription-pharmaceutical company in Pakistan.

  Action taken

  GlaxoSmithKline Consumer Healthcare Pakistan Limited was demerged from GlaxoSmithKline Pakistan Limited.

  Aftermath

  The consumer-health company began independent operations in 2016 and later became Haleon Pakistan, while GSK Pakistan remained focused on prescription medicines and vaccines.

  Source

• 2010

  Acquisition of Stiefel Laboratories operationsM&A

  Background

  GSK Pakistan continued to expand through the acquisition of another international pharmaceutical company's Pakistani operations.

  Action taken

  It acquired Stiefel Laboratories' operations in Pakistan in December 2010.

  Aftermath

  The acquisition broadened GSK Pakistan's local operating interests, although the supplied reference does not specify the transferred products or facilities.

  Source

• 2008

  Acquisition of Bristol-Myers Squibb operationsM&A

  Background

  GSK Pakistan pursued an expansion of its local pharmaceutical operations through the purchase of Bristol-Myers Squibb's Pakistani business.

  Action taken

  It acquired the Bristol-Myers Squibb operations in Pakistan in December 2008.

  Aftermath

  The transaction added another multinational pharmaceutical operation to GSK Pakistan's local business. The supplied source does not detail the resulting product or organizational changes.

  Acquisition value. Approximately US$36.5 million (December 2008)

  Source

1. 1GSK Pakistanen.wikipedia.org